A Phase I, Open-Label Trial to Investigate the Pharmacokinetic Effect of Multiple-Dose TMC125 on Buprenorphine and Norbuprenorphine Administered in HIV-Negative Subjects on Stable Buprenorphine/Naloxone Maintenance Therapy.
Phase of Trial: Phase I
Latest Information Update: 28 Oct 2010
At a glance
- Drugs Buprenorphine/naloxone; Etravirine
- Indications HIV infections
- Focus Pharmacokinetics
- Sponsors Janssen R&D Ireland
- 12 Dec 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 12 Dec 2009 Actual patient number (22) added as reported by ClinicalTrials.gov.
- 20 Oct 2009 Planned end date changed from 1 Sep 2009 to 1 Nov 2009 as reported by ClinicalTrials.gov.